2026-06-30T02:01:09Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/51132024-10-31T11:42:14Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Dondo, Tatendashe B. author Hall, Marlous author West, Robert M. author Jernberg, Tomas author Lindahl, Bertil author Bueno, Hector author Danchin, Nicolas author Deanfield, John E. author Hemingway, Harry author Fox, Keith A. A. author Timmis, Adam D. author Gale, Chris P. author 2017 BACKGROUND For acute myocardial infarction (AMI) without heart failure (HF), it is unclear if beta-blockers are associated with reduced mortality. OBJECTIVES The goal of this study was to determine the association between beta-blocker use and mortality in patients with AMI without HF or left ventricular systolic dysfunction (LVSD). METHODS This cohort study used national English and Welsh registry data from the Myocardial Ischaemia National Audit Project. A total of 179,810 survivors of hospitalization with AMI without HF or LVSD, between January 1, 2007, and June 30, 2013 (final follow-up: December 31, 2013), were assessed. Survival-time inverse probability weighting propensity scores and instrumental variable analyses were used to investigate the association between the use of beta-blockers and 1-year mortality. RESULTS Of 91,895 patients with ST-segment elevation myocardial infarction and 87,915 patients with non-ST-segment elevation myocardial infarction, 88,542 (96.4\%) and 81,933 (93.2\%) received beta-blockers, respectively. For the entire cohort, with> 163,772 person-years of observation, there were 9,373 deaths (5.2\%). Unadjusted 1-year mortality was lower for patients who received beta-blockers compared with those who did not (4.9\% vs. 11.2\%; p < 0.001). However, after weighting and adjustment, there was no significant difference in mortality between those with and without beta-blocker use (average treatment effect [ATE] coefficient: 0.07; 95\% confidence interval [CI]: -0.60 to 0.75; p = 0.827). Findings were similar for ST-segment elevation myocardial infarction (ATE coefficient: 0.30; 95\% CI: -0.98 to 1.58; p = 0.637) and non-ST-segment elevation myocardial infarction (ATE coefficient: -0.07; 95\% CI: -0.68 to 0.54; p = 0.819). CONCLUSIONS Among survivors of hospitalization with AMI who did not have HF or LVSD as recorded in the hospital, the use of beta-blockers was not associated with a lower risk of death at any time point up to 1 year. (beta-Blocker Use and Mortality in Hospital Survivors of Acute Myocardial Infarction Without Heart Failure; (C) 2017 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. J Am Coll Cardiol. 2017; 69(22):2710-2720 10.1016/j.jacc.2017.03.578 1558-3597 0735-1097 Journal of the American College of Cardiology 28571635 http://hdl.handle.net/20.500.12105/5113 average treatment effect NSTEMI Preserved left ventricular systolic function Propensity score STEMI Survival DISEASE TRIAL INTERVENTION GUIDELINES METOPROLOL MANAGEMENT ELEVATION OUTCOMES THERAPY Beta-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction